MacroGenics (NASDAQ:MGNX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

MacroGenics (NASDAQ:MGNX) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Zacks reports. The firm had revenue of $49.40 million for the quarter, compared to analysts’ expectations of $34.17 million. MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%.

MacroGenics Price Performance

Shares of MacroGenics stock opened at $2.06 on Friday. MacroGenics has a 1 year low of $2.03 and a 1 year high of $19.54. The firm has a market cap of $128.98 million, a PE ratio of -1.29 and a beta of 2.12. The company has a 50 day simple moving average of $2.68 and a two-hundred day simple moving average of $3.23.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.